According to the Guardian, ten companies that allegedly polluted air and water will not be required to pay penalties they agreed to before June 1. Questions: What total in civil penalties will not be made by these ten companies? Why are these penalties being delayed and do you believe this is a good policy? Who… Read more »
Posts Tagged: lobbying
Sports Betting in All States!
According to the New York Times, The Supreme Court struck down a federal law that effectively banned commercial sports betting in most states, boosting the prospect of such gambling across the nation. Questions: 1. Who are the winners in this decision? 2. Who are the losers in this decision? 3. According to the article, what… Read more »
Not all retirement plans are equal!
According to the New York Times, millions of Americans — public school teachers, clergy members, employees of religious institutions or nonprofits, and some charities — are not offered 401(k)’s; instead they typically must rely on what are known as 403(b) plans, many of which are more lightly regulated. Questions: 1. Briefly summarize why public school… Read more »
Is this Really a Good Thing?
According to the New York Times, private equity firms have increasingly been taking over public services, like emergency care and firefighting, often with dire effects. Questions: 1. What are the factors that private equity firms apply to public services that put these arrangements into jeopardy? 2. About how many Americans work for companies owned by… Read more »
Congressional Insider Trading?
Nineteen months ago, with only 20 minutes remaining in the trading day, a Washington-based broker-dealer, Height Securities, blasted out a “flash report” to nearly 200 clients, including hedge funds on Wall Street that predicted a raise in Medicare reimbursement rates. This sent many health insurance companies’ stocks soaring. Regulators are now trying to investigate insider… Read more »
Repatenting for Profits and the High Costs of Breathing
Unlike other countries, where the government directly or indirectly sets an allowed national wholesale price for each drug, the United States leaves prices to market competition among pharmaceutical companies, including generic drug makers. This has resulted in a vicious cycle of repatenting old drugs that use to cost pennies with new delivery systems and processes… Read more »